HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: R800016-MCP200v1 8/9/2023    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Google Scholar Articles by Franck, J. Articles by Salzet, M. PubMed PubMed Citation Articles by Franck, J. Articles by Salzet, M. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 8:2023-2033, 2009.
© 2009 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Review

MALDI Imaging Mass Spectrometry

STATE OF THE ART TECHNOLOGY IN CLINICAL PROTEOMICS^*

Julien Franck^,, Karim Arafah^,, Mohamed Elayed, David Bonnel, Daniele Vergara, Amélie Jacquet, Denis Vinatier^¶, Maxence Wisztorski, Robert Day^||, Isabelle Fournier^,** and Michel Salzet^,

From the MALDI Imaging Team, Laboratoire de Neuroimmunologie des Annélides, IFR 147, CNR-FRE 2933, University of Lille1, 59655 Villeneuve d'Ascq, France,
¶Service de gynécologie, Hôpital Jeanne de Flandre, 59037 Lille, France, and
||Département de Pharmacologie, Faculté de médecine, Université de Sherbrooke, Sherbrooke, Québec J1H 5N4, Canada

A decade after its inception, MALDI imaging mass spectrometry has become a unique technique in the proteomics arsenal for biomarker hunting in a variety of diseases. At this stage of development, it is important to ask whether we can consider this technique to be sufficiently developed for routine use in a clinical setting or an indispensable technology used in translational research. In this report, we consider the contributions of MALDI imaging mass spectrometry and profiling technologies to clinical studies. In addition, we outline new directions that are required to align these technologies with the objectives of clinical proteomics, including: 1) diagnosis based on profile signatures that complement histopathology, 2) early detection of disease, 3) selection of therapeutic combinations based on the individual patient's entire disease-specific protein network, 4) real time assessment of therapeutic efficacy and toxicity, 5) rational redirection of therapy based on changes in the diseased protein network that are associated with drug resistance, and 6) combinatorial therapy in which the signaling pathway itself is viewed as the target rather than any single "node" in the pathway.

To whom correspondence may be addressed. E-mail: michel.salzet{at}univ-lille1.fr.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?